Indication
Severe Hypertriglyceridemia
11 clinical trials
8 products
1 drug
Product
OlezarsenClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe HypertriglyceridemiaStatus: Recruiting, Estimated PCD: 2024-10-01
Product
PlaceboClinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 2b Study of ISIS 678354 in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe HypertriglyceridemiaStatus: Completed, Estimated PCD: 2023-03-22
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe HypertriglyceridemiaStatus: Recruiting, Estimated PCD: 2025-06-01
Product
PegozaferminClinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST StudyStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe HypertriglyceridemiaStatus: Recruiting, Estimated PCD: 2026-07-01
Product
PlozasiranClinical trial
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe HypertriglyceridemiaStatus: Completed, Estimated PCD: 2023-03-09
Product
ARO-APOC3Clinical trial
An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)Status: Recruiting, Estimated PCD: 2026-05-01
Product
K-877Product
FenofibrateClinical trial
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Normal Renal FunctionStatus: Completed, Estimated PCD: 2019-06-24
Clinical trial
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double--Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Mild or Moderate Renal ImpairmentStatus: Completed, Estimated PCD: 2019-07-05
Clinical trial
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe HypertriglyceridemiaStatus: Recruiting, Estimated PCD: 2026-07-01
Drug
VarlilumabClinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous Injection of DR10624 in Subjects With Severe HypertriglyceridemiaStatus: Recruiting, Estimated PCD: 2025-08-30
Product
DR10624